Figure 5. MiR-338 inhibited tumor growth in vivo and prolonged the survival period. (A) Luminescence imaging for miR-338-treated U87-luc tumors versus miR-Scr-treated controls (P<0.01, P<0.01, P<0.05, respectively). Kaplan-Meier survival curves indicating that outcomes were significantly better in mice transfected with miR-338 than in mice transfected with miR-Scr (P<0.01). (B) IHC staining revealed that PKM2 and β-catenin protein levels were lower in the miR-338-treated group than in the miR-Scr-treated group.